Citation Impact
Citing Papers
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
2009
Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine
2011 StandoutScience
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
2011 StandoutScience
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
2002
Activity of Acetyl-Ser-Asp-Lys-Pro (AcSDKP) on Human Hematopoietic Progenitor Cells in Short-Term and Long-Term Bone Marrow Cultures
2000
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
2007
Cytosine methylation regulates oviposition in the pathogenic blood fluke Schistosoma mansoni
2011 Standout
HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer
2000
Triple-Negative Breast Cancer
2010 Standout
Cancer statistics, 2020
2020 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
A prognostic score for patients with lower risk myelodysplastic syndrome
2007
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
A view on drug resistance in cancer
2019 StandoutNature
Epigenetic targets in hematopoietic malignancies
2003
Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials
1997
Epigenetics: A Landscape Takes Shape
2007 Standout
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
The Treatment of Multiple Myeloma
1994
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
2007
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
2008
Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
2006
Epigenetic therapy of cancer: past, present and future
2006
Imaging in the era of molecular oncology
2008 StandoutNature
Lung Cancer
2008 Standout
Active DNA demethylation: many roads lead to Rome
2010
Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
2013
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
Myelodysplastic Syndromes
2004
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies
2005
The Epigenomics of Cancer
2007 Standout
Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice
2004 StandoutNobel
Epigenetics in Cancer
2008 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
2018
The mighty mouse: genetically engineered mouse models in cancer drug development
2006
A Translational View of the Molecular Pathogenesis of Lung Cancer
2007
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
1999 Standout
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
2006
A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer
2000
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation
2002 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer
2000
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Decitabine—Bedside to bench
2006
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
2000 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies
1995
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy
1997 Standout
Leukaemogenesis: more than mutant genes
2009
The Epidemiology of Myelodysplastic Syndromes
2010
Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
1995
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
Prognostic molecular markers in early breast cancer
2004
Therapy with azanucleosides for myelodysplastic syndromes
2010
Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
2008
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes
2007
Hypomethylation and apoptosis in 5-azacytidine–treated myeloid cells
2008
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
1994
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Anemia of Chronic Disease
2005 Standout
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine
2007
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Chemotherapy of Metastatic Breast Cancer in the Elderly
1992
Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines
2009
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
2001
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
Acute Myeloid Leukemia
2015 Standout
Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment
2002
Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13
2005
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
2011
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
Epigenetic Reactivation of Tumor Suppressor Genes by a Novel Small-Molecule Inhibitor of Human DNA Methyltransferases
2005
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
2001
Cancer, Clinical Pharmacology, and Aging
1987
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
Silenced Tumor Suppressor Genes Reactivated by DNA Demethylation Do Not Return to a Fully Euchromatic Chromatin State
2006
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Representation of older patients in cancer treatment trials
1994
Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342
2004
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Standout
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
2007
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
2005
Works of John Ellerton being referenced
Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group.
1980
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
2017
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
1994
A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
1993
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
1995
Dose-Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741
1999
Impact of Azacytidine on the Quality of Life of Patients With Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study
2002
Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B
2002